Iron as a co-morbid factor in nonhemochromatotic liver disease

Alcohol

Volumn 30, Issue 2, 2003, Pages 137-144

  Bonkovsky, Herbert L ^a   Lambrecht, Richard W ^a   Shan, Ying ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Alcohol; Cirrhosis; End stage liver disease; Hepatitis; HFE gene; Iron; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Porphyria cutanea tarda; Portosystemic shunt

Indexed keywords

ALCOHOL LIVER DISEASE; CATALYSIS; CATALYST; CHRONIC HEPATITIS; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; GENE MUTATION; HEPATITIS C; HETEROZYGOSITY; HUMAN; INSULIN RESISTANCE; IRON THERAPY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; NONHEMOCHROMATOTIC LIVER DISEASE; OXIDATIVE STRESS; PARENCHYMA; PATHOGENICITY; PORPHYRIA CUTANEA TARDA; PORTOSYSTEMIC ANASTOMOSIS; REDUCTION; RISK FACTOR; VIRUS HEPATITIS;

HEPATITIS C VIRUS;

EID: 0041382552     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-8329(03)00127-7     Document Type: Conference Paper

References (71)

1. Adams P.C., Bradley C., Frei J.V. Hepatic iron and zinc concentrations after portacaval shunting for nonalcoholic cirrhosis. Hepatology. 19:1994;101-105.
2. Agrawal S., Bonkovsky H.L. Management of nonalcoholic steatohepatitis: an analytic review. J Clin Gastroenterol. 35:2002;253-261.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 346:2002;1221-1231.
4. Arber N., Konikoff F.M., Moshkowitz M., Baratz M., Hallak A., Santo M., Halpern Z., Weiss H., Gilat T. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci. 39:1994;2656-2659.
5. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 107:1994;1103-1109.
6. Baker J.A., Cohen M. Development of hemosiderosis after side-to-side portacaval shunting. Gastroenterology. 63:1972;491-494.
7. Barton A.L., Banner B.F., Cable E.E., Bonkovsky H.L. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol. 103:1995;419-424.
8. Bayraktar Y., Koseoglu T., Somner C., Kayhan B., Temizer A., Uzunalimoglu B., De Maria N., van Thiel D.H. The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. J Viral Hepat. 3:1996;129-135.
9. Bayraktar Y., Saglam F., Temizer A., Uzunalimodlu B., van Thiel D.H. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Hepatogastroenterology. 45:1998;2322-2327.
10. Blumberg B.S., Lustbader E.D., Whitford P.L. Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci U S A. 78:1981;3222-3224.
11. Bonkovsky H.L. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol. 97:2002;1-4.
12. Bonkovsky H.L., Banner B.F., Lambrecht R.W., Rubin R.B. Iron in liver diseases other than hemochromatosis. Semin Liver Dis. 16:1996;65-82.
13. Bonkovsky H.L., Banner B.F., Rothman A.L. Iron and chronic viral hepatitis. Hepatology. 25:1997;759-768.
14. Bonkovsky H.L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R.W., Banner B.F. Nonalcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol. 31:1999;421-429.
15. Bonkovsky H.L., Lambrecht R.W. Iron-induced liver injury. Clin Liver Dis. 4:2000;409-429.
16. Bonkovsky H.L., Obando J.V. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis. Curr Gastroenterol Rep. 1:1999;30-37.
17. Bonkovsky H.L., Poh-Fitzpatrick M., Pimstone N., Obando J., Di Bisceglie A., Tattrie C., Tortorelli K., LeClair P., Mercurio M.G., Lambrecht R.W. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 27:1998;1661-1669.
18. Bonkovsky H.L., Troy N., McNeal K., Banner B.F., Sharma A., Obando J., Mehta S., Koff R.S., Liu Q., Hsieh C. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol. 37:2002;848-854.
19. Brandhagen D.J., Alvarez W., Therneau T.M., Kruckeberg K.E., Thibodeau S.N., Ludwig J., Porayko M.K. Iron overload in cirrhosis - HFE genotypes and outcome after liver transplantation. Hepatology. 31:2000;456-460.
20. Brodanova M., Hoenig V. Iron metabolism in patients with porta-caval shunts. Scand J Gastroenterol. 1:1966;167-172.
21. Bulaj Z.J., Phillips J.D., Ajioka R.S., Franklin M.R., Griffen L.M., Guinee D.J., Edwards C.Q., Kushner J.P. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 95:2000;1565-1571.
22. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., Samarasinghe D., Lin R., Abeygunasekera S., George J. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 36:2002;142-149.
23. Clark J.M., Brancati F.L., Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology. 122:2002;1649-1657.
24. Clark J.M., Brancati F.L., Diehl A.M.E. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology. 120:2001;A65. (Abstract).
25. De Feo T.M., Fargion S., Duca L., Cesana B.M., Boncinelli L., Lozza P., Cappellini M.D., Fiorelli G. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res. 25:2001;1494-1499.
26. de Sousa M., Porto G. The immunological system in hemochromatosis. J Hepatol. 28:(Suppl):1998;1-7.
27. Deugnier Y., Moirand R., Jouanolle A.M., LeGall J.Y., Brissot P., David V. HLA-H mutations in patients with iron overload and normal transferrin saturation. Hepatology. 26:1997;199A. (Abstract).
28. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., Bacon B.R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 102:1992;2108-2113.
29. Di Bisceglie A.M., Bonkovsky H.L., Chopra S., Flamm S., Reddy R.K., Grace N., Killenberg P., Hunt C., Tamburro C., Tavill A.S., Ferguson R., Krawitt E., Banner B., Bacon B.R. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology. 32:2000;135-138.
30. Diwakaran H.H., Befeler A.S., Britton R.S., Brunt E.M., Bacon B.R. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol. 36:2002;687-691.
31. Doberneck R.C., Fischer R., Smith D. Gastrojejunostomy inhibits postshunt siderosis. Surgery. 78:1975;334-338.
32. Egger N.G., Goeger D.E., Payne D.A., Miskovsky E.P., Weinman S.A., Anderson K.E. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci. 47:2002;419-426.
33. Erhardt A., Maschner-Olberg A., Mellenthin C., Kappert G., Adams O., Donner A., Willers R., Niederau C., Haussinger D. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol. 38:2003;335-342.
34. Facchini F.S., Hua N.W., Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 122:2002;931-939.
35. Fargion S., Fracanzani A.L., Sampietro M., Molteni V., Boldorini R., Mattioli M., Cesana B., Lunghi G., Piperno A., Valsecchi C., Fiorelli G. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol. 9:1997;497-503.
36. Fargion S., Mattioli M., Sampietro M., Rossi G., Saltarin L., Lupica L., Fracanzani A.L., David E., Fassati L.R., Fiorelli G. Iron as risk factor for hepatocellular carcinoma. J Hepatol. 28:(Suppl):1998;93A. (Abstract).
37. Fong T.L., Han S.H., Tsai N.C., Morgan T.R., Mizokami M., Qian D., Phan C., Goad K., Redeker A.G. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol. 28:1998;369-374.
38. Fontana R.J., Israel J., LeClair P., Banner B.F., Tortorelli K., Grace N., Levine R.A., Fiarman G., Thiim M., Tavill A.S., Bonkovsky H.L. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 31:2000;730-736.
39. Frenzer A., Rudzki Z., Norton I.D., Butler W.J., Roberts-Thomson I.C. Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis. Scand J Gastroenterol. 33:1998;1324.
40. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D. Jr., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
41. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., Jazwinska E.C., Powell L.W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 114:1998;311-318.
42. Gorman N., Ross K.L., Walton H.S., Bement W.J., Szakacs J.G., Gerhard G.S., Dalton T.P., Nebert D.W., Eisenstein R.S., Sinclair J.F., Sinclair P.R. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology. 35:2002;912-921.
43. Grace N.D., Powell L.W. Iron storage disorders of the liver. Gastroenterology. 67:1974;1257-1283.
44. Grove J., Daly A.K., Burt A.D., Guzail M., James O.F.W., Bassendine M.F., Day C.P. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut. 43:1998;262-266.
45. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 89:1994;986-988.
46. Ikura Y., Morimoto H., Johmura H., Fukui M., Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol. 91:1996;1367-1373.
47. Kazemi-Shirazi L., Datz C., Maier-Dobersberger T., Kaserer K., Hackl F., Polli C., Steindl P.E., Penner E., Ferenci P. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology. 116:1999;127-134.
48. Lambrecht R.W., Bonkovsky H.L. Hemochromatosis and porphyria. Semin Gastrointest Dis. 13:2002;109-119.
49. Lombard C.M., Strauchen J.A. Postshunt hemochromatosis with cardiomyopathy. Hum Pathol. 12:1981;1149-1151.
50. Ludwig J., Hashimoto E., Porayko M.K., Moyer T.P., Baldus W.P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 112:1997a;882-888.
51. Ludwig J., McGill D.B., Lindor K.D. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 12:1997b;398-403.
52. Lustbader E.D., Hann H.W., Blumberg B.S. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science. 220:1983;423-425.
53. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
54. McCullough A.J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 34:2002;255-262.
55. Mendler M.H., Moirand R., Turlin B., Sapey T., Guyader D., Brissot P. Study of the HFE mutations in the "dysmetabolic iron overload syndrome" Hepatology. 28:1998;419A. (Abstract).
56. Milman N., Graudal N., Hegnhoj J., Christoffersen P., Pedersen N.S. Relationships among serum iron status markers, chemical and histochemical liver iron content in 117 patients with alcoholic and nonalcoholic hepatic disease. Hepatogastroenterology. 41:1994;20-24.
57. Pascoe A., Kerlin P., Jones D. Spur cell anemia explains the iron overload in advanced cirrhosis (C282Y negative). Hepatology. 32:2000;159.
58. Pascoe A., Kerlin P., Steadman C., Clouston A., Jones D., Powell L., Jazwinska E., Lynch S., Strong R. Spur cell anaemia acid hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation. Gut. 45:1999;301-305.
59. Pietrangelo A. Hemochromatosis gene modifies course of hepatis C viral infection. Gastroenterology. 124:2003;1509-1523.
60. Piperno A., Sampietro M., D'Alba R., Roffi L., Fargion S., Parma S., Nicoli C., Corbetta N., Pozzi M., Arosio V., Boari G., Fiorelli G. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver. 16:1996;248-254.
61. Raynard B., Balian A., Fallik D., Capron F., Bedossa P., Chaput J.C., Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 35:2002;635-638.
62. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 349:1997;321-323.
63. Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A., Corbetta N., Malosio I., Mattioli M., Fracanzani A.L., Cappellini M.D., Fiorelli G., Fargion S. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 27:1998;181-184.
64. -/- mice as a model for porphyria cutanea tarda. Hepatology. 37:2003;351-358.
65. Smith B.C., Gorve J., Guzail M.A., Day C.P., Daly A.K., Burt A.D., Bassendine M.F. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology. 27:1998;1695-1699.
66. Suzuki Y., Saito H., Suzuki M., Hosoki Y., Sakurai S., Fujimoto Y., Kohgo Y. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease. Alcohol Clin Exp Res. 26:2002;26S-31S.
67. Tannapfel A., Stolzel U., Kostler E., Melz S., Richter M., Keim V., Schuppan D., Wittekind C. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch. 439:2001;1-5.
68. Thursz M., Mantafounis D., Yallop R. Severe alcoholic liver disease is associated with the haemochromatosis gene mutant. Gastroenterology. 112:1997;1401A. (Abstract).
69. Tsukamoto H., Horne W., Kamimura S., Niemela O., Parkkila S., Yla-Herttuala S., Brittenham G.M. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:1995;620-630.
70. Yano M., Hayashi H., Wakusawa S., Sanae F., Takikawa T., Shiono Y., Arao M., Ukai K., Ito H., Watanabe K., Yoshioka K. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol. 97:2002;133-137.
71. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., McCullough A.J. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 30:1999;847-850.